See more : NAHL Group Plc (NAH.L) Income Statement Analysis – Financial Results
Complete financial analysis of Evoq Remedies Limited (EVOQ.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Evoq Remedies Limited, a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Elecnor, S.A. (ENO.MC) Income Statement Analysis – Financial Results
- Amasse Capital Holdings Limited (8168.HK) Income Statement Analysis – Financial Results
- Becle, S.A.B. de C.V. (BCCLF) Income Statement Analysis – Financial Results
- Schibsted ASA (SCHB.OL) Income Statement Analysis – Financial Results
- Japan Insulation Co., Ltd. (5368.T) Income Statement Analysis – Financial Results
Evoq Remedies Limited (EVOQ.BO)
About Evoq Remedies Limited
Evoq Remedies Ltd. engages in the provision of pharmaceutical raw materials. It offers excipients, nutraceuticals, pellets, solvents, sweeteners, vitamins, amino acids, bulk drugs, dairy products, and active pharmaceutical ingredients. The company was founded by Bhumishth Narendrabhai Patel on February 24, 2010 and is headquartered in Ahmedabad, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 63.09M | 264.13M | 167.83M | 100.25M | 90.72M | 32.50M |
| Cost of Revenue | 15.66M | 193.28M | 138.05M | 78.62M | 90.48M | 32.27M |
| Gross Profit | 47.43M | 70.85M | 29.78M | 21.63M | 242.00K | 226.00K |
| Gross Profit Ratio | 75.18% | 26.82% | 17.74% | 21.58% | 0.27% | 0.70% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 775.00K | 2.18M | 1.87M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 3.74M | 2.58M | 2.62M | 0.00 | 0.00 | 0.00 |
| SG&A | 4.52M | 4.76M | 4.49M | 1.05M | 123.00K | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 4.52M | 48.00M | 15.19M | 12.09M | 237.00K | 66.00K |
| Cost & Expenses | 20.17M | 241.28M | 153.25M | 90.71M | 90.72M | 32.34M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 72.98K | 39.00K | -14.63M | -9.54M | -5.00K | -162.00K |
| EBITDA | 6.19M | 22.90M | -46.18K | -1.83K | 0.00 | -2.00K |
| EBITDA Ratio | 9.81% | 8.67% | -0.03% | 0.00% | 0.00% | -0.01% |
| Operating Income | 42.92M | 22.86M | 14.63M | 9.54M | 5.00K | 162.00K |
| Operating Income Ratio | 68.03% | 8.65% | 8.72% | 9.52% | 0.01% | 0.50% |
| Total Other Income/Expenses | -36.80M | -13.00K | -46.18K | -11.04M | 0.00 | -66.00K |
| Income Before Tax | 6.11M | 22.85M | 14.58M | 9.54M | 5.00K | 160.00K |
| Income Before Tax Ratio | 9.69% | 8.65% | 8.69% | 9.52% | 0.01% | 0.49% |
| Income Tax Expense | 1.59M | 6.65M | 3.67M | 2.38M | 2.00K | 49.00K |
| Net Income | 4.52M | 16.19M | 10.91M | 7.15M | 3.00K | 111.00K |
| Net Income Ratio | 7.17% | 6.13% | 6.50% | 7.14% | 0.00% | 0.34% |
| EPS | 1.25 | 1.19 | 0.70 | 7.15 | 0.00 | 0.16 |
| EPS Diluted | 1.25 | 1.19 | 0.70 | 7.15 | 0.00 | 0.16 |
| Weighted Avg Shares Out | 3.62M | 13.61M | 15.59M | 1.00M | 710.06K | 710.00K |
| Weighted Avg Shares Out (Dil) | 3.62M | 13.61M | 15.59M | 1.00M | 710.00K | 710.00K |
Source: https://incomestatements.info
Category: Stock Reports